These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
97 related items for PubMed ID: 6399617
1. Cytotoxic agents in prostate cancer: an enigma. Yagoda A. Semin Urol; 1983 Nov; 1(4):311-21. PubMed ID: 6399617 [No Abstract] [Full Text] [Related]
2. [Evaluation of the effectiveness of cisplatin in the treatment of disseminated cancer of the prostate]. Nogueira March JL, Ojea A, Jamardo D, Díez E, Figueiredo L. Arch Esp Urol; 1985 Nov; 38(1):28-34. PubMed ID: 4039554 [No Abstract] [Full Text] [Related]
4. Radiopharmaceutical and chemotherapy combinations in metastatic castrate-resistant prostate cancer: a new beginning? Sartor O. J Clin Oncol; 2009 May 20; 27(15):2417-8. PubMed ID: 19364953 [No Abstract] [Full Text] [Related]
5. [Serum testosterone and acid phosphatase levels in patients with prostatic cancer treated with Estracyt]. Németh A, Morvay J, Vécsei B. Orv Hetil; 1981 Apr 26; 122(17):1017-20. PubMed ID: 7022313 [No Abstract] [Full Text] [Related]
6. Carcinoembryonic antigen as an adjunct to determination of clinical stage in prostate cancer. Kane RD, Paulson DF. Natl Cancer Inst Monogr; 1978 Dec 26; (49):231. PubMed ID: 748775 [Abstract] [Full Text] [Related]
7. Current trials using bone-targeting agents in prostate cancer. Tu SM, Lin SH. Cancer J; 2008 Dec 26; 14(1):35-9. PubMed ID: 18303481 [Abstract] [Full Text] [Related]
8. Pharmacoclinical study of oral estramustine phosphate (Estracyt) in advanced carcinoma of the prostate. Müntzing J, Shukla SK, Chu TM, Mittelman A, Murphy GP. Invest Urol; 1974 Jul 26; 12(1):65-8. PubMed ID: 4835492 [No Abstract] [Full Text] [Related]
11. Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group Trial. Moore MR, Troner MB, DeSimone P, Birch R, Irwin L. Cancer Treat Rep; 1986 Apr 26; 70(4):541-2. PubMed ID: 3698053 [No Abstract] [Full Text] [Related]
12. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates. Green JR. Acta Oncol; 2005 Apr 26; 44(3):282-92. PubMed ID: 16076701 [Abstract] [Full Text] [Related]
14. Systemic therapeutic strategies for prostate cancer. Nelson WG. Clin Adv Hematol Oncol; 2005 Aug 26; 3(8):619-21. PubMed ID: 16167046 [No Abstract] [Full Text] [Related]
15. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Tiffany NM, Wersinger EM, Garzotto M, Beer TM. Urology; 2004 May 26; 63(5):934-9. PubMed ID: 15134984 [Abstract] [Full Text] [Related]
16. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE. J Natl Cancer Inst; 2005 Jan 05; 97(1):59-69. PubMed ID: 15632381 [Abstract] [Full Text] [Related]
17. Chemotherapy for advanced prostate cancer: 25 years later. Logothetis CJ, Millikan R. J Clin Oncol; 2008 May 20; 26(15):2423-4. PubMed ID: 18487561 [No Abstract] [Full Text] [Related]
18. Chemotherapy in advanced prostate cancer. Beedassy A, Cardi G. Semin Oncol; 1999 Aug 20; 26(4):428-38. PubMed ID: 10482185 [Abstract] [Full Text] [Related]